Verastem (VSTM) Stock Forecast & Price Target

Verastem is supported by compelling clinical differentiation in recurrent LGSOC, where avutometinib plus defactinib showed a 71% lower risk of progression or death in KRAS-mutant patients and a 42% reduction in KRAS wild-type patients versus matched conventional care, alongside higher response rates and longer median PFS. The company’s commercial footing is also improving, with AVMAPKI/FAKZYNJA CO-PACK net product revenue of $25.1M in 2Q26, a 34% sequential rebound, and management indicating the franchise may become financially self-sustaining by YE26. Its balance sheet was strengthened by a non-dilutive royalty deal and a $15M milestone, lifting pro forma cash to $201.4M and extending runway into 2H 2027, while mid-2027 RAMP 301 data could broaden the label and expand the addressable market.

Verastem is exposed to substantial clinical and regulatory uncertainty, since its late-stage oncology assets may fail to show meaningful efficacy or secure approval on a workable timeline, any of which would weaken commercial prospects. It also faces intense competitive pressure from better-resourced commercial and development-stage peers, while the valuation itself depends on very aggressive assumptions, including FY37 GAAP EPS of $4.31 and an 18x multiple discounted at 12%, making execution risk unusually high. Financially, the need for additional equity financing to complete development raises dilution risk, and the change in FV preferred warrant liability underscores ongoing balance-sheet complexity and volatility.